Evidence map›Paper›PMID 28155868›Full record

ArticleScientific reports2017

A critical role for p38MAPK signalling pathway during reprogramming of human fibroblasts to iPSCs.

Irina Neganova, Valeria Chichagova, Lyle Armstrong, Majlinda Lako

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Metabolic control of induced pluripotency.Frontiers in cell and developmental biology · 2023
    Review
  13. Article
  14. Frontiers in cardiovascular medicine · 2022
    Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Irina NeganovaInstitute of Genetic Medicine, Newcastle University, International Centre for Life, NE1 3BZ, UK.
Valeria ChichagovaInstitute of Genetic Medicine, Newcastle University, International Centre for Life, NE1 3BZ, UK.
Lyle ArmstrongInstitute of Genetic Medicine, Newcastle University, International Centre for Life, NE1 3BZ, UK.
Majlinda LakoInstitute of Genetic Medicine, Newcastle University, International Centre for Life, NE1 3BZ, UK.
Newcastle University · GBCentre for Life · GB

Funding

Biotechnology and Biological Sciences Research Council BB/E012841/1British Heart Foundation PG/12/60/29799European Research Council 614620Medical Research Council G0301182
6 · The paper itself

Abstract

Reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) holds enormous promise for regenerative medicine. Reprogramming is a stepwise process with well-defined stages of initiation, maturation and stabilisation which are critically dependent on interactions between key pluripotency transcription factors, epigenetic regulators and signalling pathways. In this manuscript we have investigated the role of p38 MAPK signalling pathway and have shown a subpopulation- and phase-specific pattern of activation occurring during the initiation and maturation stage of reprogramming in partially and fully reprogrammed cells respectively. Downregulation of p38 MAPK activity via RNA interference or small molecule inhibitor led to cell accumulation in G1 phase of the cell cycle and reduced expression of cell cycle regulators during the initiation stage of reprogramming. This was associated with a significant downregulation of key pluripotency marker expression, disruption of mesenchymal to epithelial transition (MET), increased expression of differentiation markers and presence of partially reprogrammed cells which retained a typical gene expression profile of mesendodermal cells and were unable to progress to fully reprogrammed phenotype. Together our data indicate an important role for p38 MAPK activity in proliferation, MET progression and establishment of pluripotent phenotype, which are necessary steps for the development of human iPSCs.

Indexed as

Cellular ReprogrammingMAP Kinase Signaling SystemBiomarkersCell CycleCell LineCells, CulturedEpithelial-Mesenchymal TransitionFibroblastsGene Expression Regulation, DevelopmentalHumansInduced Pluripotent Stem CellsProtein Kinase InhibitorsBiomarkersProtein Kinase Inhibitors

Identifiers

PMID28155868
PMCPMC5290526
OpenAlexW2583288452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.